Ocular ischemic syndrome (OIS) is a disease seen in cardiology, ophthalmology, neurology, and neurosurgery, which can lead to brain and ocular symptoms induced by carotid artery obstruction or stenosis. In local and general manifestation, ocular symptoms usually appear first. Ocular symptoms show the prewarning effect of other ischemic damage. Ophthalmologists should pay attention to the clinical manifestation and damages of OIS. The establishment of multidisciplinary diagnosis and treatment patterns for OIS is a pivotal issue for several disciplines.
Objective To observe the effect of ophthalmotonus intervention on ocular hemodynamics in patients with ischemic ophthalmopathy (IOP). Methods 106 IOP patients (106 eyes) were enrolled in this study, including 74 eyes with nonarteritic anterior ischemic optic neuropathy (NAION), 20 eyes with retinal artery occlusion (RAO) and 12 eyes with ocular ischemia syndrome (IOS). The patients were randomly divided into ophthalmotonus intervention group and control group. There were 37 NAION eyes, 10 RAO eyes and six IOS eyes in each group. The patients of ophthalmotonus intervention group received lowering intraocular pressure treatment in addition to the basic therapy to reduce the intraocular pressure to le;12 mm Hg (1 mm Hg=0.133 kPa) or decreased by 7-8 mm Hg, or in a 20%-30% reduction. The patients of control group avoided lowering intraocular pressure treatment. The arm-retinal circulation time (A-RCT) and the peak systolic velocity (PSV), end diastolic velocity (EDV) and resistance index (RI) of ophthalmic artery (OA), central retinal artery (CRA) and short posterior ciliary arteries (PCA) before and one week after treatment were comparatively analyzed by fluorescence fundus angiography (FFA) and color Doppler flow imaging. Results The differences of A-RCT before treatment in ophthalmotonus intervention group and control group in NAION, RAO and IOS patients were not statistically significant (t=0.869, 0.119, 0.000; P＞0.05). The differences of PSV (OA:t=0.586, 0.040, 0.067; CRA:t=0.285, 0.057, 0.775; PCA:t=0.658, 0.653, 1.253), EDV (OA:t=0.274, 0.080, 0.093; CRA:t=0.781, 0.077, 0.277; PCA:t=0.200, 0.209, 0.299) and RI (OA:t=0.121, 0.153, 0.138; CRA:t=0.172, 0.242, 0.642; PCA:t=1.053, 1.066, 0.266) of OA, CRA and PCA before treatment in ophthalmotonus intervention group and control group were not statistically significant (P＞0.05). Compared with control group, A-RCT shortened obviously (t=2.573, 2.236, 2.607; P＜0.05) in ophthalmotonus intervention group one week after treatment. Compared with control group, PSV (OA:t=2.367, 2.368, 2.267; CRA:t=0.775, 1.927, 2.775; PCA:t=2.253, 2.353, 2.353) and EDV (OA:t=2.303, 2.236, 2.503; CRA: t=2.277, 2.377, 2.577; PCA:t=2.299, 2.399, 2.299) of OA, CRA and PCA increased obviously (P＜0.05), RI of OA, CRA and PCA decreased obviously (OA:t=2.238, 2.387, 2.228; CRA:t=2.342, 2.442, 2.542; PCA:t=2.266, 2.366, 2.266; P＜0.05) one week after treatment in treatment group. Conclusion Ophthalmotonus intervention can improve the ocular hemodynamics in IOP patients.
ObjectiveTo observe the effects of carotid artery stenting (CAS) on ophthalmic artery blood flow in patients with ischemic ophthalmopathy (IOP).MethodsA prospective case-control study. Sixty IOP patients (60 eyes) who met inclusive criteria for CAS were enrolled in this study. There was 50% stenosis of internal carotid artery on one side at least confirmed by color doppler flow imaging (CDFI). Among 60 eyes, there were 3 eyes with central retinal artery occlusion, 15 eyes with retinal vein occlusion, 37 eyes with ischemic optic neuropathy, 5 eyes with ocular ischemia syndrome. The patients were randomly divided into CAS group (32 eyes of 32 patients) and medicine therapy group (28 eyes of 28 patients). The difference of age (t=1.804) and sex (χ2=1.975) between two groups was not significant (P＞0.05). The examinations of fundus fluorescein angiography (FFA), CDFI and digital substraction angiography (DSA) were performed before, 1 week and 6 months after treatment. The following parameters were recorded: arm-retinal circulation time (A-Rct), peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistance index (RI) in the ophthalmic artery (OA) and central retinal artery (CRA), and the best corrected visual acuity (BCVA).ResultsThere was no significant differences in A-Rct (t=1.354) and BCVA (t=0.376) between the two groups before treatment (P＞0.05). Also, there was no significant differences in PSV (t=−0.294, −2.446), EDV (t=0.141, −0.305), and RI (t=−0.222, −0.694) of OA and CRA between the two groups before treatment before treatment (P＞0.05). Compared with the medicine therapy group, the lower A-Rct was found in the CAS group at different time points after the treatment. The difference was significant on 1 week after treatment (t=−3.205, P＜0.05), but not on 6 months after treatment (t=1.345, P＞0.05). The BCVA of eyes in the two groups were increasing with the extending of time of therapy. Compared with the medicine therapy group, the better BCVA was found in the CAS group at different time points after the treatment (t=0.800, 1.527; P＜0.05). Compared with the medicine therapy group, the higher PSV, EDV and lower RI of OA and CRA were found in the CAS group at different time points after the treatment. (P＜0.05).ConclusionCompared with conventional medicine therapy, CAS shows earlier effects in improving ocular hemodynamics for IOP patients with carotid artery stenosis, which benefits visual function improvement of the patients.